1279032-06-2

Basic information

• Product Name: 4-(4-BroMo-2-Methylphenyl)Morpholine
• Synonyms: 4-(4-BroMo-2-Methylphenyl)Morpholine
• CAS NO: 1279032-06-2
• Molecular Formula: C₁₁H₁₄BrNO
• Molecular Weight: 256.13896
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 1279032-06-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-BroMo-2-Methylphenyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BroMo-2-Methylphenyl)Morpholine(1279032-06-2)
• EPA Substance Registry System: 4-(4-BroMo-2-Methylphenyl)Morpholine(1279032-06-2)

Safety Data

• Hazardous Substances Data: 1279032-06-2(Hazardous Substances Data)

Usage

Uses

4-(4-Bromo-2-methylphenyl)-morpholine is used in the synthesis of aminoquinoline derivatives as antiviral agents.

Upstream product

• 111-44-4 3-oxa-1,5-dichloropentane 
• 583-75-5 4-Bromo-2-methylaniline 

Relevant articles and documents

Method for synthesizing substitution N-phenylmorpholine compounds

The invention discloses a method for synthesizing substitution N-phenylmorpholine compounds. Substituted aniline and 2-chloroethyl ether are heated under the effect of alkali and then are subjected to ring closure to obtain the N-phenylmorpholine compound

GLYCINE COMPOUND

[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.